the INFECTIOUS DISEASES channel
Open in Telegram
🌀The aim of this group is to make the Infectious Diseases and it’s related issues more logical and easy. 🌀Will try to share useful information in this fantastic field. 🌀Supervised by Dr. Alaa Alali Ⓜ️&🆔 🌀So, you are welcome 🙏🏻
Show more9 038
Subscribers
No data24 hours
+57 days
+7630 days
Data loading in progress...
Similar Channels
Tags Cloud
Incoming and Outgoing Mentions
---
---
---
---
---
---
Attracting Subscribers
September '26
September '26
+24
in 0 channels
August '26
+150
in 0 channels
Get PRO
July '26
+223
in 0 channels
Get PRO
June '26
+112
in 0 channels
Get PRO
May '26
+139
in 0 channels
Get PRO
April '26
+139
in 0 channels
Get PRO
March '26
+99
in 0 channels
Get PRO
February '26
+126
in 0 channels
Get PRO
January '26
+106
in 0 channels
Get PRO
December '25
+121
in 0 channels
Get PRO
November '25
+117
in 1 channels
Get PRO
October '25
+162
in 0 channels
Get PRO
September '25
+218
in 0 channels
Get PRO
August '25
+200
in 0 channels
Get PRO
July '25
+213
in 0 channels
Get PRO
June '25
+222
in 0 channels
Get PRO
May '25
+195
in 0 channels
Get PRO
April '25
+226
in 0 channels
Get PRO
March '25
+236
in 0 channels
Get PRO
February '25
+246
in 0 channels
Get PRO
January '25
+354
in 0 channels
Get PRO
December '24
+338
in 0 channels
Get PRO
November '24
+318
in 0 channels
Get PRO
October '24
+299
in 0 channels
Get PRO
September '24
+305
in 0 channels
Get PRO
August '24
+258
in 0 channels
Get PRO
July '24
+111
in 0 channels
Get PRO
June '24
+100
in 0 channels
Get PRO
May '24
+141
in 0 channels
Get PRO
April '24
+105
in 0 channels
Get PRO
March '24
+101
in 0 channels
Get PRO
February '24
+123
in 0 channels
Get PRO
January '24
+178
in 0 channels
Get PRO
December '23
+4 505
in 0 channels
| Date | Subscriber Growth | Mentions | Channels | |
| 08 September | +2 | |||
| 07 September | +3 | |||
| 06 September | +3 | |||
| 05 September | +6 | |||
| 04 September | +1 | |||
| 03 September | +4 | |||
| 02 September | +2 | |||
| 01 September | +3 |
Channel Posts
| 2 | 🎙️4th Sep 2026
Respiratory Virus Vaccines: Evidence of Effectiveness and Safety
https://jamanetwork.com/journals/jama/pages/jama-editors-summary
🎙️September 6, 2026
POET trial Prose and Cons
https://share.transistor.fm/s/d5eb49ac
🎙️2nd Sep 2026
Infectious Disease Puscast, Daniel and Sara review the infectious disease literature
https://podcasts.apple.com/sa/podcast/infectious-disease-puscast/id1622649470?i=1000787474776
🎙️26th Aug 2026
Who Do You Listen To? The Hidden Influencers of Hand Hygiene
https://infectioncontrolmatters.com/2026/08/26/who-do-you-listen-to-the-hidden-influencers-of-hand-hygiene/
🎙️4th Aug 2026
Infections in Hematologic Malignancies and Stem Cell Transplantation
https://idpodcasts.net/podcasts/infections-in-hematologic-malignancies-and-stem-cell-transplantation/
🎙️31 July 2026
Outbreak Summer
https://podcasts.apple.com/us/podcast/outbreak-summer-vacation-souvenirs-you-never-wanted/id1748955344?i=1000779300765 | 555 |
| 3 |  +3🦠 Know the bug
⚙️ Know the mechanism
🧫 Check the susceptibility
🎯 Control the source
💊 Choose the narrowest effective therapy
💥 IDSA 2026. 🦠💊
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag481/8756906 | 748 |
| 4 | https://youtu.be/S33Mz6dks0k?si=Y6k36o5Ixv6ZCPZH | 867 |
| 5 |  https://jamanetwork.com/ | 1 117 |
| 6 | The latest international AIDS meeting took place in Rio de Janeiro highlights
https://voices.nejm.org/doi/full/10.1056/VOICESpost2600043?query=voices_ps&cid=DM2461488_&bid=-649123859 | 2 193 |
| 7 | Ask the Expert, focusing on the diagnosis and management of pyelonephritis in kidney transplant recipients.
https://www.tts.org/tid-education/tid-ask-the-expert | 2 549 |
| 8 | The curious case of thick-walled buds and a pink lung!
https://www.idimages.org/m/cases/viewfeatured/?caseid=625&fbclid=IwT01FWATj7GdwZG9mBWV4dG4DYWVtAjEwAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHqv45QzJRcxA3rL6FvwR46G1-rK6NKF1hLisW4WrGjj4KvhRhm5eAmnX5YN1_aem_uAsZ91Ag6pAML-7aQvFRJQ | 2 174 |
| 9 | Infections in Hematologic Malignancies and Stem Cell Transplantation
https://youtu.be/v0Vl7ui1mVQ?si=9L4jZRj9tY0_bW45 | 1 955 |
| 10 |  Dana M. Blyth; Clinton K. Murray
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 318, 3774-3781.e3 | 1 810 |
| 11 |  +6Source: Nix C, Bisht A. Infection Prevention in Oncology. In: APIC Text Online. Association for Professionals in Infection Control and Epidemiology (APIC); 2026. | 2 286 |
| 12 | 🦠 IDSA 2026 AMR Gram-Negative Guidance
What's New? | July 2026
🔵 ESBL-Producing Enterobacterales (ESBL-E)
🧪 New ESBL definition
Ceftriaxone MIC ≥4 µg/mL
💊 New agents added
✅ Gepotidacin
✅ Pivmecillinam
✅ Oral sulopenem
✅ IV fosfomycin
✅ Cefepime-enmetazobactam (emerging role)
📌 Practice update
Piperacillin-tazobactam may be considered for complicated UTI (not first choice for invasive disease).
---
🟢 AmpC-Producing Enterobacterales
🦠 New organism
Hafnia alvei added as moderate-risk AmpC producer.
📌 Key updates
Continue ceftriaxone if:
Non-severe infection
Clinical improvement
Adequate source control
⚠️ Piperacillin-tazobactam appears suboptimal for invasive AmpC infections.
---
🔴 Carbapenem-Resistant Enterobacterales (CRE)
⭐ Major advance
Aztreonam-avibactam introduced for NDM-producing CRE and is slightly preferred over ceftazidime-avibactam + aztreonam.
🆕 Added:
IV fosfomycin
Gepotidacin
Pivmecillinam
🔬 Updated comparisons:
Ceftazidime-avibactam vs Meropenem-vaborbactam
Aztreonam-avibactam vs Cefiderocol
---
🟣 Difficult-to-Treat (DTR) Pseudomonas aeruginosa
🏆 Preferred for uncomplicated UTI
Single-dose amikacin or tobramycin
🫁 Pneumonia
Ceftolozane-tazobactam preferred over ceftazidime-avibactam.
💨 Nebulised antibiotics:
Still not routinely recommended, but evidence is becoming more favourable.
---
🟠 Carbapenem-Resistant Acinetobacter baumannii (CRAB)
🥇 First-line therapy
Sulbactam-durlobactam + carbapenem
⏳ Alternative regimens:
Only as bridge therapy until sulbactam-durlobactam becomes available.
If resistant:
Two active non-sulbactam agents or
Sulbactam-durlobactam + cefiderocol
---
🟡 Stenotrophomonas maltophilia
⭐ Preferred therapy
Cefiderocol monotherapy
➕ Aztreonam-avibactam added as part of combination therapy for selected invasive infections.
---
🚨 Top 6 Take-Home Messages
✅ New FDA-approved antibiotics incorporated into guidance.
✅ Aztreonam-avibactam is now preferred for NDM-producing CRE.
✅ Sulbactam-durlobactam becomes the cornerstone of invasive CRAB treatment.
✅ Ceftolozane-tazobactam is favoured for DTR Pseudomonas pneumonia.
✅ Piperacillin-tazobactam has a limited role (acceptable for some complicated ESBL UTIs but generally not for invasive AmpC infections).
✅ Updated microbiology definitions and resistance epidemiology should guide antimicrobial stewardship and empiric therapy.
> Bottom line: The 2026 IDSA guidance expands therapeutic options, emphasises newer β-lactam/β-lactamase inhibitor combinations, refines laboratory interpretation, and strengthens precision treatment based on resistance mechanisms.
https://www.idsociety.org/practice-guideline/amr-guidance/ | 2 110 |
| 13 |  +2No text... | 1 636 |
| 14 |  +1No text... | 1 730 |
| 15 |  +1https://www.pha.gov.sa/ar-sa/Pages/default.aspx | 1 646 |
| 16 |  https://cidsupdate.cidsindia.org/all-books/68b6926e785095ca78382485?chapterId=68b69c5b785095ca78382e23 | 1 806 |
| 17 |  +3Latent TB pearls ✨️ | 2 391 |
| 18 |  +2No text... | 2 017 |
| 19 |  +2No text... | 2 119 |
| 20 |  Photo from Mohammed Alabdullah ID | 2 434 |
